DrugPatentWatch Database Preview
Drugs in Development Information for ABX464
» See Plans and Pricing
What is the drug development status for ABX464?
ABX464 is an investigational drug.
There have been 12 clinical trials for ABX464.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2020.
The most common disease conditions in clinical trials are Colitis, HIV Infections, and Ulcer. The leading clinical trial sponsors are Abivax S.A., FLS-RS, and [disabled in preview].
There are eleven US patents protecting this investigational drug and two hundred and six international patents.
Summary for ABX464
| US Patents | 11 |
| International Patents | 206 |
| US Patent Applications | 20 |
| WIPO Patent Applications | 26 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2020-05-01) |
| Vendors | 18 |
Recent Clinical Trials for ABX464
| Title | Sponsor | Phase |
|---|---|---|
| ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19 | Abivax S.A. | Phase 2/Phase 3 |
| Study Evaluating the One-Year Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis | Abivax S.A. | Phase 2 |
| Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis | Abivax S.A. | Phase 2 |
Clinical Trial Summary for ABX464
Top disease conditions for ABX464
Top clinical trial sponsors for ABX464
US Patents for ABX464
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ABX464 | Start Trial | Compounds useful for treating AIDS | ABIVAX (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) INSTITUT CURIE (Paris, FR) UNIVERSITE DE MONTPELLIER (Montpellier, FR) | Start Trial |
| ABX464 | Start Trial | Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging | ABIVAX (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) INSTITUT CURIE (Paris, FR) UNIVERSITE DE MONTPELLIER (Montpellier, FR) | Start Trial |
| ABX464 | Start Trial | Treatments to eliminate HIV reservoirs and reduce viral load | INSTITUT PASTEUR (Paris, FR) | Start Trial |
| ABX464 | Start Trial | Quinoline derivative for use in the treatment and prevention of viral infections | ABIV AX (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) INSTITUT CURIE (Paris, FR) UNIVERSITE DE MONTPELLIER (Montpellier, FR) | Start Trial |
| ABX464 | Start Trial | Quinoline derivatives for the treatment of inflammatory diseases | ABIVAX (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR) INSTITUT CURIE (Paris, FR) UNIVERSITE DE MONTPELLIER (Montpellier, FR) | Start Trial |
| ABX464 | Start Trial | Process for preparing quinolin-2-yl-phenylamine derivatives and their salts | RATIOPHARM GMBH (Ulm, DE) | Start Trial |
| ABX464 | Start Trial | Compounds useful for treating cancer | ABIVAX (Paris, FR) CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (Paris, FR) INSTITUT CURIE (Paris, FR) UNIVERSITE MONTPELLIER 2 (Montpellier, FR) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ABX464
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ABX464 | Australia | AU2010258214 | 2029-06-12 | Start Trial |
| ABX464 | Australia | AU2010258294 | 2029-06-12 | Start Trial |
| ABX464 | Australia | AU2010258295 | 2029-06-12 | Start Trial |
| ABX464 | Australia | AU2015203256 | 2029-06-12 | Start Trial |
| ABX464 | Australia | AU2017202500 | 2029-06-12 | Start Trial |
| ABX464 | Australia | AU2019203896 | 2029-06-12 | Start Trial |
| ABX464 | Brazil | BR122019013686 | 2029-06-12 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
